Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by gebremeskelon Jul 08, 2024 12:50pm
252 Views
Post# 36122981

It's a small world after all...

It's a small world after all...In May 2015 the Carlisle Group hired Baxter's current CEO, Jose Almeida, to help them find investment opportunities in the medical field. He worked there only 6 months - until October 2015 when he was appointed CEO of Baxter.

The Carlyle Group Names Jos E. Almeida Operating Executive for Global Healthcare Team

News Release
 
MON, 04 MAY 2015
 
Former Covidien Chairman, President and CEO to Provide Leadership to Portfolio Companies and Strategic Guidance During Investment Process 
 
Washington, DC – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that Jos (Joe) E. Almeida, former Chairman, President and CEO of Covidien, will join the firm as an Operating Executive in the Global Healthcare group, effective immediately.  Mr. Almeida was instrumental in the sale of Covidien to Medtronic plc in January 2015 for $50 billion, creating the leading global medical device manufacturing company.
 
As an Operating Executive, Mr. Almeida will provide strategic guidance and advice to Carlyle professionals and portfolio company executives on the healthcare industry.  In particular, he brings a wealth of experience to Carlyle’s global investment efforts in medical technology, in vitro diagnostics, life science tools, and pharmaceutical products and services.  Mr. Almeida joins a group of more than 25 senior business executives – with an average of more than 40 years of experience – who help Carlyle to invest wisely and create value across a range of industries.  Mr. Almeida will also continue to devote time to various roles outside of the firm.
 
Stephen H. Wise, Carlyle Managing Director and Co-head of the Global Healthcare team, said, “Joe is a proven leader in the global healthcare industry with deep sector knowledge and significant experience operating in local markets around the world.  He will be a great resource to our investment professionals as we evaluate new opportunities as well as to our portfolio executive teams, including Ortho Clinical Diagnostics where Joe is a member of the Board of Directors.”
 
Mr. Almeida said, “I am excited to partner with the Carlyle healthcare team as they search globally for investment opportunities.  Carlyle’s global reach and industry expertise can be combined with my deep operational and managerial experience to form differentiated views as healthcare investors, and ultimately create value for their fund investors.”
 
Since inception, Carlyle has invested approximately $7 billion of equity in more than 40 transactions in the healthcare space, including Rede D’Or, Ortho Clinical Diagnostics, PPD, Qualicorp, Healthscope, HCR ManorCare and Multiplan.
 
Mr. Almeida joined Tyco Healthcare, the predecessor to Covidien, in 1995 where he served across multiple roles, including as President and CEO since 2011 and Chairman of the Board since 2012. Prior to being appointed CEO, Mr. Almeida was President of the Medical Devices organization at Covidien and he previously held leadership positions at Greatbatch Technologies, Inc., American Home Products’ Acufex Microsurgical division and Johnson & Johnson’s Professional Products division.
 
He served as Chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors, and he is currently on the Board of Directors of Ortho Clinical Diagnostics, State Street Corporation, EMC, and Analog Devices.
 
Mr. Almeida earned his BS in mechanical engineering from Escola de Engenharia Maua in So Paulo, Brazil.
<< Previous
Bullboard Posts
Next >>